EUVIMEDObjevte EUVIMED
Crossref

Patient‐Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study

Massimo Triggiani iD, Jessica Hobart iD, Iván Alvarez-Twose, Cristina Bulai Livideanu iD, Franziska Ruëff iD, Stéphane Barete, Patrizia Bonadonna iD, Laurence Bouillet iD, Nauman M Butt, Mark Drummond, Mar Guilarte iD, Karin Hartmann iD and 14 more

Clinical & Experimental Allergy · 2025

DOI: 10.1111/cea.70101 ↗

At a glance

Journal article in Clinical & Experimental Allergy, 2025. Written by Massimo Triggiani and 25 co-authors. Institution: Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy. Major MEDLINE topics: Mastocytosis, Systemic, Patient Reported Outcome Measures, Health Personnel. Cited 1 times so far (Crossref); 33 references. Funded by: Blueprint Medicines Corporation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Systemic mastocytosis (SM) is a clonal mast cell disease primarily driven by the KIT D816V mutation and often characterised by unpredictable and debilitating symptoms. The Perceptions Realities and Insights on Systemic Mastocytosis (PRISM) survey queried patient and provider perceptions of SM in Europe.

Methods

PRISM (funded by Blueprint Medicines Corporation) was composed of two independent surveys: a 119‐item patient survey on diagnosis, symptom burden, quality of life (QoL) and work impact; and a 103‐item healthcare provider (HCP) survey on approaches to SM diagnosis and management.

Results

Data were evaluated from 540 patient respondents from Italy ( n = 136), France ( n = 112), the UK ( n = 101), Germany ( n = 83), Spain ( n = 64), Austria ( n = 26) and Switzerland ( n = 18). Patients reported a high symptom burden and reduced physical functioning and mental health due to SM, despite taking, on average, seven medications. A majority of patients reported that SM impacted their ability to work (58.9%). A total of 618 HCP responses were collected from Italy ( n = 203), Germany ( n = 123), the UK ( n = 110), Austria ( n = 63), France ( n = 56), Switzerland ( n = 44) and Spain ( n = 19). Various HCP types reported treating patients with SM; the majority were haematologists/oncologists ( n = 167) and general practitioners ( n = 178). HCPs perceived that SM impacted their patients' QoL, with 54% reporting SM affected patients' lives ‘quite a bit’. The most frequently reported treatment goals were improving QoL and survival.

Conclusions

PRISM is the largest international and first European survey to evaluate the burden of SM from both patient and HCP perspectives. Patients and HCPs perceived a high symptom burden, reduced QoL and reduced ability to work due to SM.

Subjects

MeSH terms (MEDLINE)

Mastocytosis, SystemicPatient Reported Outcome MeasuresHealth PersonnelHumansFemaleMaleQuality of LifeMiddle AgedAdultEuropeAgedSurveys and Questionnaires

Author keywords

cross‐sectional studiesdisease burdenhealthcare provider (HCP) perceptionspatient‐reported outcomessystemic mastocytosis

Authors and institutions

  • Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
  • The UK Mastocytosis Support Group, London, UK.
  • Institute of Mastocytosis Studies of Castilla-La Mancha (CLMast), Toledo, Spain.
  • Department of Dermatology, French Reference Center for Mastocytosis (CEREMAST), Toulouse University Hospital, Toulouse, France.
  • Department of Dermatology and Allergy, University Hospital Ludwig-Maximilian University of Munich, Munich, Germany.
  • Unit of Dermatology Reference Centre for Mastocytosis (CEREMAST) AP-HP, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.

ORCID profiles: Massimo Triggiani, Jessica Hobart, Cristina Bulai Livideanu, Franziska Ruëff, Patrizia Bonadonna, Laurence Bouillet, Mar Guilarte, Karin Hartmann, Dakota Powell, Deepti H Radia, Ruben Mesa

Funding

  • Blueprint Medicines Corporation

Cite

APA

Triggiani, M., Hobart, J., Alvarez-Twose, I., Livideanu, C. B., Ruëff, F., Barete, S., Bonadonna, P., Bouillet, L., Butt, N. M., Drummond, M., Guilarte, M., Hartmann, K., Beaux, A., Finnerty, C. C., Hegmann, N., Marcis, P., Ribada, E., Schinhofen, W., Coletti, G., …, & Mesa, R. (2025). Patient‐Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70101

Vancouver

Triggiani M, Hobart J, Alvarez-Twose I, Livideanu CB, Ruëff F, Barete S, et al. Patient‐Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70101

BibTeX
@article{Triggiani2025,
  author = {Triggiani, Massimo and Hobart, Jessica and Alvarez-Twose, Iván and Livideanu, Cristina Bulai and Ruëff, Franziska and Barete, Stéphane and Bonadonna, Patrizia and Bouillet, Laurence and Butt, Nauman M and Drummond, Mark and Guilarte, Mar and Hartmann, Karin and Beaux, Amélie and Finnerty, Celeste C and Hegmann, Nicole and Marcis, Patrizia and Ribada, Eugenia and Schinhofen, Waltraud and Coletti, Gabriela and Dugdale, Andrew and Perez, Cristian and Powell, Dakota and Green, Teresa and Sullivan, Erin and Radia, Deepti H and Mesa, Ruben},
  title = {Patient‐Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  doi = {10.1111/cea.70101}
}
Start for free →